Shots:

• The P-II RELIANCE study evaluates relma-cel in 59 patients with r/r LBCL who had failed 2L of therapy- including CD20 agent- anthracycline & patients continue to be monitored for ≥2yrs. for LTO
• As of Dec 31- 2020 cut-off data- Relma-cel showed durable responses & survival benefit; ORR (77.6%); CR rate (51.7%) & 1yrs. OS (76.8%) with a median follow-up of 17.9mos. The therapy was well-tolerated with a safety profile including a low severe CRS & NT rate of ≥grade 3 (5.1% & 3.4%) & no new safety signals were observed
• Relma-cel is 1st CAR-T product approved as category 1 biologics in China. The therapy has received PR- BTD & is included in National Significant New Drug Development Program

  | Ref: PR Newswire | Image: FinSMEs